Related Experiment Videos
In vitro activity of the ketolide ABT-773.
A L Barry1, P C Fuchs, S D Brown
1The Clinical Microbiology Institute, 9725 S.W. Commerce Circle, Wilsonville, OR 97070, USA. cmi@hevanet.com
Antimicrobial Agents and Chemotherapy
|September 15, 2001
Summary
ABT-773 demonstrates potent in vitro activity against staphylococci, including macrolide-resistant strains. This novel antibiotic also effectively inhibits Streptococcus pneumoniae and other streptococci, showing promise in combating resistant bacterial infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing global health concern.
- Novel antimicrobial agents are needed to combat resistant bacterial pathogens.
- Macrolide and clindamycin resistance are significant challenges in treating staphylococcal and streptococcal infections.
Purpose of the Study:
- To compare the in vitro antibacterial activity of ABT-773 against azithromycin, erythromycin, and clindamycin.
- To evaluate the efficacy of ABT-773 against a diverse collection of clinical isolates, including resistant strains.
- To assess the potency of ABT-773 against key bacterial species such as Staphylococcus, Streptococcus pneumoniae, and Haemophilus influenzae.
Main Methods:
- Testing of 1,223 clinical isolates representing various bacterial species and phenotypes.
- Determination of minimum inhibitory concentrations (MICs) for ABT-773, azithromycin, erythromycin, and clindamycin.
- Inclusion of macrolide-resistant and clindamycin-susceptible strains for comparative analysis.
Main Results:
- ABT-773 exhibited high potency against staphylococci, with a minimum inhibitory concentration (MIC(90)) of less than or equal to 0.06 microg/ml.
- This included activity against all tested strains resistant to macrolides but susceptible to clindamycin.
- ABT-773 effectively inhibited Streptococcus pneumoniae and other streptococci, including erythromycin-resistant strains, at low concentrations.
- Against Haemophilus influenzae, ABT-773 showed comparable potency to azithromycin (MIC(90) of 4.0 microg/ml vs. 2.0 microg/ml).
Conclusions:
- ABT-773 demonstrates significant in vitro antibacterial activity across a range of clinically relevant pathogens.
- Its potent activity against resistant staphylococci and streptococci suggests potential as a valuable therapeutic agent.
- Further investigation into ABT-773's clinical efficacy is warranted.